/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Outlook Therapeutics (OTLK) generated about n/a in revenue and -$61 million in net income (a -4,416.2% net margin) over the trailing twelve months, growing at roughly -23.0% a year. Figures are from SEC filings; this is analysis, not investment advice.
Outlook Therapeutics reported about -$61 million in net loss over the trailing twelve months, a net margin of roughly -4,416.2%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Outlook Therapeutics runs a gross margin of about 4.0%, an operating margin of about -4,744.3%, a net margin of about -4,416.2%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
Outlook Therapeutics's revenue has compounded at roughly -23.0% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside OTLK's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 15 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 16 May 2026. How this is calculated.
Fiscal year ends Sep.